News and Analysis

Priothera lands Series A

Dublin, Ireland-based Priothera Limited, a developer of orally applied sphingosine 1 phosphate receptor modulators for haematological malignancies, has secured 30 million euros in Series A financing.

Iris Dorbian

12 October 2020

Dublin, Ireland-based Priothera Limited, a developer of orally applied sphingosine 1 phosphate receptor modulators for haematological malignancies, has secured 30 million euros in Series A financing. Fountain Healthcare Partners and HealthCap led the round.

Source: Press Release

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Nearly there!

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.